Patents by Inventor David D. Roberts
David D. Roberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240135388Abstract: A computer executed process for mimicking human dialog, referred to herein as a “humanoid” or “humanoid system,” can be configured to provide automated customer support. The humanoid can identify a support issue for a customer, as well as a customer support campaign corresponding to the support issue. The humanoid can identify at least one machine learning model associated with the customer support campaign and can communicate with the customer using the at least one machine learning model. The humanoid can execute a support action to resolve the support issue.Type: ApplicationFiled: October 29, 2023Publication date: April 25, 2024Inventors: David C. White, JR., Jay K. Johnston, Magnus Mortensen, Christopher Shaun Roberts, Kevin D. McCabe
-
Publication number: 20240125253Abstract: A valve actuation system comprises a first arm having a first arm contact surface and operatively connected to a valve actuation motion. A second arm having a second arm contact surface is operatively connected to the at least one engine valve. A discrete lost motion device is provided that is controllable between a first, motion conveying state and a second, motion absorbing state. The discrete lost motion devices comprises a plunger contact surface and a housing contact surface. The housing contact surface is configured to engage one of the first or second arm contact surfaces, and the plunger contact surface is configured to engage another of the first and the second arm contact surfaces. The first and second arm contact surfaces, the housing contact surface and the first plunger contact surface are configured to support the discrete lost motion device between the first arm and the second arm.Type: ApplicationFiled: October 10, 2023Publication date: April 18, 2024Inventors: Bruce A. SWANBON, Justin D. BALTRUCKI, Robb JANAK, G. Michael GRON, JR., John MANDELL, Marc B. SILVA, Tyler HINES, Matei ALEXANDRU, Austen P. METSACK, Gabriel S. ROBERTS, P. Douglas AUBIN, Nathaniel P. HASSALL, John Jerl PURCELL, III, Adam C. CECIL, David M. BARNES
-
Patent number: 11914849Abstract: A method for enhancing interaction between a customer and a customer service representative of a company is provided. A graphical user interface (GUI) of a windows control tool is displayed. A type of an interaction between the customer and the customer service representative at a computer operated by the company is determined. One or more applications associated with the type of interaction are launched based on a predetermined display layout associated with the type of interaction. One or more application windows corresponding to the launched applications are arranged on a screen based on the predetermined display layout associated with the type of interaction. The windows control tool is configured to control the one or more application windows based on customer service representative's input. The GUI of the windows control tool displays a plurality of window objects corresponding to the one or more launched applications.Type: GrantFiled: November 10, 2020Date of Patent: February 27, 2024Assignee: United Services Automobile AssociationInventors: David W. Roberts, Aaron Quade, Steven D. Sternitzke
-
Publication number: 20240002811Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.Type: ApplicationFiled: May 19, 2023Publication date: January 4, 2024Inventors: David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
-
Patent number: 11692175Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.Type: GrantFiled: July 24, 2019Date of Patent: July 4, 2023Assignee: The USA, as represented by, the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
-
Publication number: 20220184111Abstract: Disclosed herein are methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. Example disclosed methods reduce cardiotoxicity of a chemotherapeutic agent. Also disclosed are methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the chemotherapeutic agent.Type: ApplicationFiled: February 28, 2022Publication date: June 16, 2022Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: David D. Roberts, David R. Soto Pantoja
-
Patent number: 11285169Abstract: Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.Type: GrantFiled: March 13, 2014Date of Patent: March 29, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, David R. Soto Pantoja
-
Patent number: 11254735Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: GrantFiled: June 17, 2019Date of Patent: February 22, 2022Assignees: The United States of America, as represented by the Secretary, Depar tment of Health and Human Services, Washington UniversityInventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Publication number: 20210355495Abstract: Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47.Type: ApplicationFiled: June 14, 2021Publication date: November 18, 2021Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Chengyu Liu
-
Patent number: 11053314Abstract: Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47.Type: GrantFiled: October 9, 2015Date of Patent: July 6, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Chengyu Liu
-
Publication number: 20200095306Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: ApplicationFiled: June 17, 2019Publication date: March 26, 2020Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Washington UniversityInventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Publication number: 20200071677Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.Type: ApplicationFiled: July 24, 2019Publication date: March 5, 2020Inventors: David D. ROBERTS, Sukhbir KAUR, Jeffrey S. ISENBERG
-
Patent number: 10407665Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.Type: GrantFiled: April 9, 2013Date of Patent: September 10, 2019Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
-
Patent number: 10370439Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: GrantFiled: September 29, 2014Date of Patent: August 6, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Isenberg, David D. Roberts
-
Publication number: 20180355032Abstract: Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47.Type: ApplicationFiled: October 9, 2015Publication date: December 13, 2018Applicant: The U.S.A, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Chengyu Liu
-
Publication number: 20160222097Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: ApplicationFiled: September 29, 2014Publication date: August 4, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Jeffrey S. Isenberg, David D. Roberts
-
Publication number: 20160045532Abstract: Disclosed herein are methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. Example disclosed methods reduce cardiotoxicity of a chemotherapeutic agent. Also disclosed are methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the chemotherapeutic agent.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Inventors: David D. Roberts, David R. Soto Pantoja
-
Publication number: 20150111768Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.Type: ApplicationFiled: April 9, 2013Publication date: April 23, 2015Inventors: David D. ROBERTS, Sukhbir Kaur, Jeffrey S. Enberg
-
Patent number: 8951527Abstract: Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.Type: GrantFiled: August 5, 2009Date of Patent: February 10, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Isenberg, David D. Roberts, Justin Maxhimer
-
Patent number: 8865672Abstract: Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: GrantFiled: July 11, 2012Date of Patent: October 21, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Isenberg, David D. Roberts